Otsuka is moving deeper into neuroplastogen approaches for PTSD via a planned acquisition of Transcend Therapeutics for $1.22 billion. The deal, announced by Otsuka, expands Otsuka’s neuroscience portfolio with Transcend’s pipeline focused on drug-discovery programs targeting mechanisms tied to synaptic plasticity and post-traumatic stress pathology. In another specialty transaction, Aurinia named Kevin Tang as CEO and is pursuing an acquisition of Kezar, a move that signals ongoing consolidation in autoimmune-focused drug development. Tang’s prior attempt to acquire Kezar underscores that the deal cycle has been active over multiple years. Both moves reflect a continued sector preference for acquiring late-stage optionality and platform-adjacent pipeline assets rather than building from scratch, particularly in competitive neuro and autoimmune markets.